LONDON & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Positive results from the IMPACT study demonstrate that patients with homogeneous emphysema benefit from treatment with Pulmonx Corporation’s ...
WASHINGTON & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung ...
LONDON, United Kingdom — An endobronchial valve placed in the lung of a patient with homogeneous emphysema can lead to clinically meaningful improvements in lung function, exercise tolerance, and ...
Bilateral heterogenous emphysema was the most comment presentation in patients referred for bronchoscopic lung volume reduction (BLVR), based on data from more than 200 individuals presented at the ...
At 12 months, the average improvement from baseline on the 10-point BODE index -- the study's primary endpoint -- was a similar -1.10 (SD 1.44) with LVRS and -0.82 (1.61) with BLVR (P=0.54), Sara ...
New Data Presented at ATS 2021 International Conference Shows Positive, Sustained Benefits to Patients Treated with this First Minimally Invasive, Non-drug Treatment Option REDWOOD CITY, Calif., May ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback